Elevance Health Files 8-K

TL;DR

ELEVANCE HEALTH FILED A STANDARD 8-K ON 3/4/24. NO MAJOR NEWS.

AI Summary

Elevance Health, Inc. filed an 8-K on March 4, 2024, to disclose information under Regulation FD. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for this form type.

Why It Matters

This filing indicates Elevance Health is adhering to its reporting obligations with the SEC, which is standard practice for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for Regulation FD disclosure and does not report any new material events or financial changes.

Key Players & Entities

• Elevance Health, Inc. (company) — Registrant
• Indiana (jurisdiction) — State of incorporation
• March 4, 2024 (date) — Date of report

FAQ

From the Filing

0001193125-24-056688.txt : 20240304 0001193125-24-056688.hdr.sgml : 20240304 20240304060754 ACCESSION NUMBER: 0001193125-24-056688 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240304 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20240304 DATE AS OF CHANGE: 20240304 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elevance Health, Inc. CENTRAL INDEX KEY: 0001156039 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] ORGANIZATION NAME: 02 Finance IRS NUMBER: 352145715 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-16751 FILM NUMBER: 24712755 BUSINESS ADDRESS: STREET 1: 220 VIRGINIA AVENUE CITY: INDIANAPOLIS STATE: IN ZIP: 46204 BUSINESS PHONE: 8003311476 MAIL ADDRESS: STREET 1: 220 VIRGINIA AVENUE CITY: INDIANAPOLIS STATE: IN ZIP: 46204 FORMER COMPANY: FORMER CONFORMED NAME: Anthem, Inc. DATE OF NAME CHANGE: 20141202 FORMER COMPANY: FORMER CONFORMED NAME: WELLPOINT, INC DATE OF NAME CHANGE: 20100105 FORMER COMPANY: FORMER CONFORMED NAME: WELLPOINT INC DATE OF NAME CHANGE: 20041130 8-K 1 d806565d8k.htm 8-K 8-K false 0001156039 0001156039 2024-03-04 2024-03-04     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 4, 2024 Date of Report (Date of earliest event reported)     Elevance Health, Inc. (Exact name of registrant as specified in its charter)       Indiana   001-16751   35-2145715 (State or other jurisdiction of incorporation or organization)   (Commission File Number)   (I.R.S. Employer Identification Number)   220 Virginia Ave Indianapolis , IN 46204 (Address of principal executive offices and zip code) (833) 401-1577 (Registrant’s telephone number, including area code)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol   Name of each exchange on which registered Common Stock, Par Value $0.01   ELV   NYSE Indicate by check mark whether the registrant is an emerging growth company as defined Rule 405 of the Securities Act (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       Item 7.01 - Regulation FD Disclosure Officers of Elevance Health, Inc. (the “Company”) will speak with investors over the next several weeks. During these meetings, Company officers intend to reaffirm the Company’s net income guidance for full year 2024 to be greater than $34.29 per diluted share, including approximately $2.81 per diluted share of net unfavorable items. Excluding these items, the Company continues to expect adjusted net income to be greater than $37.10 per diluted share. In addition, the Company officers will also report that the Centers for Medicare&#16